South Korea Infertility Market Overview
The South Korea Infertility Market is expanding as infertility awareness increases and demand for advanced reproductive healthcare continues to grow. Technological advancements in assisted reproductive technologies, government support for fertility treatments, changing social attitudes, delayed childbearing, and greater awareness of reproductive health are supporting market development in South Korea.
According to the Market Research Future report updated August 24, 2026, the South Korea Infertility Market was valued at USD 61.06 Million in 2024 and is projected to grow from USD 68.89 Million in 2025 to USD 230.15 Million by 2035, registering a CAGR of 12.82% during 2025–2035. Assisted Reproductive Technology represents the largest type segment, Hormone Therapy is the fastest-growing type, Hospitals account for the largest end-user segment, Fertility Clinics are the fastest-growing end user, Female treatments represent the largest gender segment, Male treatments are emerging rapidly, and Ovulatory Disorders represent the largest cause of infertility.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/sample_request/45520
Key players driving innovation and competitiveness in the South Korea Infertility Market include:
CooperSurgical
Merck KGaA
Ferring Pharmaceuticals
Irvine Scientific
Vitrolife
Reproductive Health Technologies
OvaScience
Genea
The market is being shaped by rising infertility rates, advances in reproductive medicine, government financial support, increasing awareness, and changing attitudes toward infertility treatment. IVF, intracytoplasmic sperm injection, preimplantation genetic testing, cryopreservation, and other assisted reproductive technologies are expanding treatment options and supporting market growth.
The South Korea Infertility Market can be segmented by Type into Assisted Reproductive Technology, Hormone Therapy, Surgery, and Fertility Preservation. By Gender, it includes Female and Male. By End User, it covers Hospitals, Fertility Clinics, and Home Care Settings. By Cause of Infertility, it includes Ovulatory Disorders, Uterine or Cervical Abnormalities, Tubal Factors, and Male Factor Infertility.
The growing need for effective fertility services is creating opportunities for reproductive-health companies, fertility clinics, hospitals, pharmaceutical companies, diagnostic providers, and assisted-reproduction technology developers. AI-driven fertility tracking, telehealth consultations, advanced reproductive technologies, personalized treatment protocols, and improved fertility-preservation solutions can support future market development.
Recent Developments and Market Trends:
Assisted Reproductive Technology remains the largest type segment, supported by the widespread use of IVF, ICSI, and other advanced procedures for infertility treatment.
Hormone Therapy is the fastest-growing type segment as patients seek less invasive treatment options for hormonal and reproductive conditions.
Surgery continues to play an important role for infertility cases requiring correction of structural or reproductive abnormalities.
Fertility Preservation is gaining attention as individuals increasingly consider options for preserving reproductive potential for future family planning.
Hospitals represent the largest end-user segment because of their comprehensive reproductive-health infrastructure, specialist teams, diagnostic capabilities, and ability to perform advanced procedures.
Fertility Clinics are the fastest-growing end-user segment as patients increasingly seek specialized, personalized fertility services and focused reproductive-care programs.
Female treatments represent the largest gender segment, reflecting the established demand for services such as ovarian stimulation, IVF, and intrauterine insemination.
Male infertility is receiving greater attention as healthcare providers and patients increasingly recognize male-related factors in infertility. Treatments and diagnostic services focused on sperm health and male reproductive conditions are therefore creating additional opportunities.
Ovulatory Disorders represent the largest cause-of-infertility segment, supported by demand for hormonal therapies, diagnostic testing, and assisted reproductive procedures.
Male Factor Infertility is emerging as a fast-growing area as awareness, diagnosis, and treatment of male reproductive factors increase.
Rising infertility rates are supporting market expansion. MRFR reports that approximately 15% of couples in South Korea face infertility issues, with delayed marriage, lifestyle changes, and environmental influences contributing to the trend.
Government policies and financial support for fertility treatments are helping reduce the financial burden on couples and improve access to reproductive healthcare services.
Growing awareness and educational initiatives are encouraging more individuals to seek medical advice and treatment while helping reduce the stigma associated with infertility.
Changing family-planning patterns are influencing demand for fertility services. Later marriage and delayed childbearing can increase the need for reproductive-health assessment and fertility treatment.
Advances in IVF and preimplantation genetic testing are improving treatment options and enabling more personalized approaches to reproductive care.
Cryopreservation technologies are creating additional opportunities by providing patients with options for preserving reproductive material and supporting fertility-treatment planning.
Digitalization and artificial intelligence are increasingly influencing fertility care. AI-based tools can support fertility tracking, treatment planning, data analysis, and patient monitoring.
Telehealth is creating opportunities for remote fertility consultations and follow-up services, improving convenience for patients who may not be able to frequently visit specialized clinics.
Personalized treatment protocols are gaining importance as fertility providers use patient-specific clinical information to tailor reproductive treatments.
Recent competitive developments highlighted by MRFR include Merck KGaA’s October 2025 strategic partnership with a South Korean fertility clinic to develop personalized treatment protocols, Ferring Pharmaceuticals’ September 2025 launch of a fertility medication for IVF procedures, and CooperSurgical’s November 2025 expansion through a new South Korean manufacturing facility for reproductive-health products.
Industry developments also include expanding fertility programs at Hallym University Medical Center and Asan Medical Center, reproductive-medicine research by the Korea Institute of Science and Technology, and continued development of IVF capabilities at major healthcare institutions.
Partnerships among healthcare institutions and research organizations, including initiatives involving the Korea Hospital Association, Sooam Biotech Research Foundation, and Yonsei University Health System, are supporting continued development of fertility care and reproductive research.
Reasons to Buy the Report:
Provides comprehensive insights into the South Korea Infertility Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across assisted reproductive technology, hormone therapy, surgery, and fertility preservation.
Offers detailed segmentation analysis across type, gender, end user, and cause of infertility.
Includes competitive intelligence covering leading reproductive-health, pharmaceutical, biotechnology, and fertility-technology companies.
Supports informed decisions using market forecasts, infertility trends, government support, technological advancements, personalized treatment, and emerging reproductive-health opportunities.
Future Outlook:
The future of the South Korea Infertility Market will be shaped by technological advancements, increasing infertility awareness, government support, changing family-planning patterns, and continued development of assisted reproductive technologies. Market Research Future projects the market to reach USD 230.15 Million by 2035 at a CAGR of 12.82% during 2025–2035.
Assisted Reproductive Technology should remain the largest type segment, while Hormone Therapy is positioned for strong growth as less invasive fertility-treatment options gain attention. Surgery and Fertility Preservation should continue to contribute to the market as treatment options become more diverse.
Hospitals should remain the largest end-user segment, while Fertility Clinics are expected to expand as specialized and personalized reproductive-care services become more widely adopted. Female treatments should continue to represent a major segment, while Male Factor Infertility is expected to gain greater attention through improved diagnosis and treatment.
AI-driven fertility tracking, telehealth, personalized treatment protocols, advanced IVF technologies, preimplantation genetic testing, cryopreservation, and continued investment in reproductive-health research are expected to influence the next phase of infertility-care development in South Korea.
➤➤Explore Our Latest Related Reports:
